Egro Francesco M, Schilling Benjamin K, Fisher James D, Saadoun Rakan, Rubin J Peter, Marra Kacey G, Solari Mario G
Department of Plastic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Department of Bioengineering, School of Engineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
J Hand Microsurg. 2024 Apr 16;16(1):100011. doi: 10.1055/s-0042-1757182. eCollection 2024 Mar.
Microsurgical techniques have revolutionized the field of reconstructive surgery and are the mainstay for complex soft tissue reconstruction. However, their limitations have promoted the development of viable alternatives. This article seeks to explore technologies that have the potential of revolutionizing microsurgical reconstruction as it is currently known, reflect on current and future vascularized composite allotransplantation (VCA) practices, as well as describe the basic science within emerging technologies and their potential translational applications.
A literature review was performed of the technologies that may represent the future of microsurgery: vascularized tissue engineering (VCA) and flap-specific tissue engineering.
VCA has shown great promise and has already been employed in the clinical setting (especially in face and limb transplantation). Immunosuppression, logistics, cost, and regulatory pathways remain barriers to overcome to make it freely available. Vascularized and flap-specific tissue engineering remain a laboratory reality but have the potential to supersede VCA. The capability of creating an off-the-shelf free flap matching the required tissue, size, and shape is a significant advantage. However, these technologies are still at the early stage and require significant advancement before they can be translated into the clinical setting.
VCA, vascularized tissue engineering, and flap-specific bioengineering represent possible avenues for the evolution of current microsurgical techniques. The next decade will elucidate which of these three strategies will evolve into a tangible translational option and hopefully bring a paradigm shift of reconstructive surgery.
显微外科技术给重建外科领域带来了变革,是复杂软组织重建的主要手段。然而,其局限性推动了可行替代技术的发展。本文旨在探索有可能变革当前已知显微外科重建技术的相关技术,反思当前及未来的血管化复合组织异体移植(VCA)实践,并描述新兴技术中的基础科学及其潜在的转化应用。
对可能代表显微外科未来的技术进行了文献综述,这些技术包括血管化组织工程(VCA)和皮瓣特异性组织工程。
VCA已展现出巨大潜力,并且已应用于临床(尤其是面部和肢体移植)。免疫抑制、后勤保障、成本及监管途径仍是需要克服的障碍,以便能广泛应用。血管化和皮瓣特异性组织工程目前仍处于实验室阶段,但有潜力取代VCA。能够制造出符合所需组织、大小和形状的现成游离皮瓣是一项显著优势。然而,这些技术仍处于早期阶段,在转化为临床应用之前还需要取得重大进展。
VCA、血管化组织工程和皮瓣特异性生物工程是当前显微外科技术发展可能的途径。未来十年将阐明这三种策略中的哪一种会发展成为切实可行的转化选择,并有望给重建外科带来范式转变。